| abstract |
The present invention provides multivalent CD20 binding molecules and compositions thereof, such as enriched compositions comprising a large proportion of multivalent CD20 binding molecules relative to monovalent CD20 binding molecules. Certain multivalent CD20 binding molecules of the invention comprise 1) two or more CD20 binding regions and 2) one or more Shiga toxin effector polypeptide regions derived from the A subunit of a member of the Shiga toxin family. Certain multivalent CD20 binding molecules of the present invention, and compositions thereof, are useful for selective killing of specific cell types and as therapeutics for the treatment of various diseases, including cancer, tumors, and immune disorders. Certain multivalent CD20-binding molecules of the invention and compositions thereof are useful for delivering agents into CD20-expressing cells, including for intracellular labeling of CD20-expressing cells, collecting diagnostic information, and monitoring a variety of CD20-expressing cells involved treatment of diseases such as cancer, tumors and immune disorders. |